Bastos F, Cross JH (2020) Epilepsy. Handb Clin Neurol 174:137–158. https://doi.org/10.1016/b978-0-444-64148-9.00011-9

Article  PubMed  Google Scholar 

Guerrini R (2006) Epilepsy in children. Lancet 367(9509):499–524. https://doi.org/10.1016/s0140-6736(06)68182-8

Article  PubMed  Google Scholar 

Tolaymat A, Nayak A, Geyer JD, Geyer SK, Carney PR (2015) Diagnosis and management of childhood epilepsy. Curr Probl Pediatr Adolesc Health Care 45(1):3–17. https://doi.org/10.1016/j.cppeds.2014.12.002

Article  PubMed  Google Scholar 

Beydoun A, Kutluay E (2002) Oxcarbazepine. Expert Opin Pharmacother 3(1):59–71. https://doi.org/10.1517/14656566.3.1.59

Article  CAS  PubMed  Google Scholar 

Abou-Khalil BW (2022) Update on antiseizure medications 2022. Continuum (Minneap Minn) 28(2):500–535. https://doi.org/10.1212/con.0000000000001104

Article  PubMed  Google Scholar 

Tecoma ES (1999) Oxcarbazepine. Epilepsia 40(Suppl 5):S37-46. https://doi.org/10.1111/j.1528-1157.1999.tb00918.x

Article  CAS  PubMed  Google Scholar 

Emilien G, Maloteaux JM (1998) Pharmacological management of epilepsy. Mechanism of action, pharmacokinetic drug interactions, and new drug discovery possibilities. Int J Clin Pharmacol Ther 36(4):181–194

CAS  PubMed  Google Scholar 

Chen Y-T, Wang C-Y, Yin Y-W, Li Z-R, Lin W-W, Zhu M, Jiao Z (2021) Population pharmacokinetics of oxcarbazepine: a systematic review. Expert Rev Clin Pharmacol 14(7):853–864. https://doi.org/10.1080/17512433.2021.1917377

Article  CAS  PubMed  Google Scholar 

Northam RS, Hernandez AW, Litzinger MJ, Minecan DN, Glauser TA, Mangat S, Zheng C, Souppart C, Sturm Y (2005) Oxcarbazepine in infants and young children with partial seizures. Pediatr Neurol 33(5):337–344. https://doi.org/10.1016/j.pediatrneurol.2005.05.011

Article  PubMed  Google Scholar 

Wang Y, Zhang HN, Niu CH, Gao P, Chen YJ, Peng J, Liu MC, Xu H (2014) Population pharmacokinetics modeling of oxcarbazepine to characterize drug interactions in Chinese children with epilepsy. Acta Pharmacol Sin 35(10):1342–1350. https://doi.org/10.1038/aps.2014.76

Article  CAS  PubMed  PubMed Central  Google Scholar 

Peng J, Zhang HN, Liu ZS, Xu H, Wang Y (2014) Population pharmacokinetics of oxcarbazepine active metabolite in Chinese children with epilepsy. Int J Clin Pharmacol Ther 52(8):684–692. https://doi.org/10.5414/cp202078

Article  CAS  PubMed  Google Scholar 

Sugiyama I, Bouillon T, Yamaguchi M, Suzuki H, Hirota T, Fink M (2015) Population pharmacokinetic analysis for 10-monohydroxy derivative of oxcarbazepine in pediatric epileptic patients shows no difference between Japanese and other ethnicities. Drug Metab Pharmacokinet 30(2):160–167. https://doi.org/10.1016/j.dmpk.2014.12.002

Article  CAS  PubMed  Google Scholar 

Chen CY, Zhou Y, Cui YM, Yang T, Zhao X, Wu Y (2019) Population pharmacokinetics and dose simulation of oxcarbazepine in Chinese paediatric patients with epilepsy. J Clin Pharm Ther 44(2):300–311. https://doi.org/10.1111/jcpt.12792

Article  CAS  PubMed  Google Scholar 

Lin WW, Li XW, Jiao Z, Zhang J, Rao X, Zeng DY, Lin XH, Wang CL (2019) Population pharmacokinetics of oxcarbazepine active metabolite in Chinese paediatric epilepsy patients and its application in individualised dosage regimens. Eur J Clin Pharmacol 75(3):381–392. https://doi.org/10.1007/s00228-018-2600-8

Article  CAS  PubMed  Google Scholar 

Wu W, Yang WS, Xu XY, Ge XL, Lu J, Wang GF, Wang Y, Li ZP (2024) Population pharmacokinetics of oxcarbazepine active metabolite in Chinese paediatric patients with epilepsy: model-based dose optimization. Basic Clin Pharmacol Toxicol 134(5):712–726. https://doi.org/10.1111/bcpt.14000

Article  CAS  PubMed  Google Scholar 

May TW, Korn-Merker E, Rambeck B (2003) Clinical pharmacokinetics of oxcarbazepine. Clin Pharmacokinet 42(12):1023–1042. https://doi.org/10.2165/00003088-200342120-00002

Article  CAS  PubMed  Google Scholar 

Flesch G (2004) Overview of the clinical pharmacokinetics of oxcarbazepine. Clin Drug Investig 24(4):185–203. https://doi.org/10.2165/00044011-200424040-00001

Article  CAS  PubMed  Google Scholar 

Johannessen Landmark C, Johannessen SI, Patsalos PN (2020) Therapeutic drug monitoring of antiepileptic drugs: current status and future prospects. Expert Opin Drug Metab Toxicol 16(3):227–238. https://doi.org/10.1080/17425255.2020.1724956

Article  CAS  PubMed  Google Scholar 

Hiemke C, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, Eckermann G, Egberts K, Gerlach M, Greiner C, Gründer G, Haen E, Havemann-Reinecke U, Hefner G, Helmer R, Janssen G, Jaquenoud E, Laux G, Messer T, Mössner R, Müller MJ, Paulzen M, Pfuhlmann B, Riederer P, Saria A, Schoppek B, Schoretsanitis G, Schwarz M, Gracia MS, Stegmann B, Steimer W, Stingl JC, Uhr M, Ulrich S, Unterecker S, Waschgler R, Zernig G, Zurek G, Baumann P (2018) Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry 51(1–02):9–62. https://doi.org/10.1055/s-0043-116492

Article  CAS  PubMed  Google Scholar 

Patsalos PN, Spencer EP, Berry DJ (2018) Therapeutic drug monitoring of antiepileptic drugs in epilepsy: a 2018 update. Ther Drug Monit 40(5):526–548. https://doi.org/10.1097/FTD.0000000000000546

Article  CAS  PubMed  Google Scholar 

Patsalos PN, Berry DJ, Bourgeois BF, Cloyd JC, Glauser TA, Johannessen SI, Leppik IE, Tomson T, Perucca E (2008) Antiepileptic drugs–best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia 49(7):1239–1276. https://doi.org/10.1111/j.1528-1167.2008.01561.x

Article  CAS  PubMed  Google Scholar 

Al-Qurain AA, Upton RN, Tadros R, Roberts MS, Wiese MD (2022) Population pharmacokinetic model for tramadol and O-desmethyltramadol in older patients. Eur J Drug Metab Pharmacokinet 47(3):387–402. https://doi.org/10.1007/s13318-022-00756-x

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li X, Wei S, Wu H, Zhang Q, Zhao Z, Mei S, Feng W, Wu Y (2023) Population pharmacokinetics of oxcarbazepine active metabolite in Chinese children with epilepsy. Eur J Pediatr 182(10):4509–4521. https://doi.org/10.1007/s00431-023-05092-z

Article  CAS  PubMed  Google Scholar 

Patsalos PN (2022) Oxcarbazepine. In: Patsalos PN (ed) Antiseizure medication interactions: a clinical guide. Springer International Publishing, pp 107–110

Li YQ, Chen KF, Ding JJ, Tan HY, Yang N, Lin YQ, Wu CF, Xie YL, Yang GP, Liu JJ, Pei Q (2021) External evaluation of published population pharmacokinetic models of polymyxin B. Eur J Clin Pharmacol 77(12):1909–1917. https://doi.org/10.1007/s00228-021-03193-y

Article  CAS  PubMed  Google Scholar 

Huang W, Zheng Y, Huang H, Cheng Y, Liu M, Chaphekar N, Wu X (2022) External evaluation of population pharmacokinetic models for voriconazole in Chinese adult patients with hematological malignancy. Eur J Clin Pharmacol 78(9):1447–1457. https://doi.org/10.1007/s00228-022-03359-2

Article  CAS  PubMed  Google Scholar 

Comets E, Brendel K, Mentré F (2008) Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R. Comput Methods Programs Biomed 90(2):154–166. https://doi.org/10.1016/j.cmpb.2007.12.002

Article  PubMed  Google Scholar 

Hanafin PO, Nation RL, Scheetz MH, Zavascki AP, Sandri AM, Kwa AL, Cherng BPZ, Kubin CJ, Yin MT, Wang J, Li J, Kaye KS, Rao GG (2021) Assessing the predictive performance of population pharmacokinetic models for intravenous polymyxin B in critically ill patients. CPT Pharmacometrics Syst Pharmacol 10(12):1525–1537. https://doi.org/10.1002/psp4.12720

Article  CAS  PubMed  PubMed Central